Oseltamivir resistance - Disabling our influenza defenses

New England Journal of Medicine

Volumn 353, Issue 25, 2005, Pages 2633-2636

  Moscona, Anne ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIBIOTIC THERAPY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; GENE MUTATION; HUMAN; INFLUENZA; PATHOGENICITY; PHYSICIAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; VALIDATION PROCESS; VIRULENCE; VIRUS LOAD; VIRUS REPLICATION;

ACETAMIDES; BINDING SITES; CHILD; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PYRANS; SELF ADMINISTRATION; SIALIC ACIDS; ZANAMIVIR;

EID: 29144433925     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp058291     Document Type: Review

References (5)

1. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73.
2. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among in-fluenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366:1175-81.
3. Varghese JN, Smith PW, Sollis SL, et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 1998;6:735-46.
4. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-85.
5. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med 2005;4:107-16.